Impact of a product-specific reference standard for the measurement of a PEGylated rFVIII activity: the Swiss Multicentre Field Study.

Bulla, O; Poncet, A; Alberio, L; Asmis, L M; Gähler, A; Graf, L; Nagler, Michael; Studt, J-D; Tsakiris, D A; Fontana, P (2017). Impact of a product-specific reference standard for the measurement of a PEGylated rFVIII activity: the Swiss Multicentre Field Study. Haemophilia, 23(4), e335-e339. Wiley 10.1111/hae.13250

[img] Text
MN_Bulla_et_al-2017-Haemophilia_Impact of a product-specific reference.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (169kB) | Request a copy

INTRODUCTION Measuring factor VIII (FVIII) activity can be challenging when it has been modified, such as when FVIII is pegylated to increase its circulating half-life. Use of a product-specific reference standard may help avoid this issue. AIM Evaluate the impact of using a product-specific reference standard for measuring the FVIII activity of BAX 855 - a pegylated FVIII - in eight of Switzerland's main laboratories. METHODS Factor VIII-deficient plasma, spiked with five different concentrations of BAX 855, plus a control FVIII sample, was sent to the participating laboratories. They measured FVIII activity by using either with a one-stage (OSA) or the chromogenic assay (CA) against their local or a product-specific reference standard. RESULTS When using a local reference standard, there was an overestimation of BAX 855 activity compared to the target concentrations, both with the OSA and CA. The use of a product-specific reference standard reduced this effect: mean recovery ranged from 127.7% to 213.5% using the OSA with local reference standards, compared to 110% to 183.8% with a product-specific reference standard, and from 146.3% to 182.4% using the CA with local reference standards compared to 72.7% to 103.7% with a product-specific reference standard. CONCLUSION In this in vitro study, the type of reference standard had a major impact on the measurement of BAX 855 activity. Evaluation was more accurate and precise when using a product-specific reference standard.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Unit Childrens Hospital > Forschungsgruppe Hämatologie (Erwachsene)

UniBE Contributor:

Nagler, Michael

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1351-8216

Publisher:

Wiley

Language:

English

Submitter:

Katrin Kölliker-Schütz

Date Deposited:

11 Dec 2017 08:18

Last Modified:

11 Dec 2017 08:18

Publisher DOI:

10.1111/hae.13250

PubMed ID:

28544263

Uncontrolled Keywords:

in vitro blood coagulation blood coagulation tests drug monitoring factor VIII procoagulant activity haemophilia A

BORIS DOI:

10.7892/boris.106211

URI:

https://boris.unibe.ch/id/eprint/106211

Actions (login required)

Edit item Edit item
Provide Feedback